Can­cer drugs among US goods spared from tar­iffs as Chi­na is­sues first ex­emp­tions in trade war

In its first move to spare cer­tain US im­ports from the trade war, Chi­na has of­fered some re­lief to can­cer drug­mak­ers.

Twelve drugs — most­ly chemother­a­py agents — fea­tured on the list of prod­ucts to be ex­empt­ed from re­tal­ia­to­ry tar­iffs un­til Sep­tem­ber 2020. They al­so be­long to the sub­group where tar­iffs al­ready col­lect­ed will be re­turned.

As­traZeneca’s EGFR in­hibitor Ires­sa ap­pears to be the on­ly non-chemo drug in the group. Here’s the list, trans­lat­ed from the Min­istry of Fi­nance’s orig­i­nal an­nounce­ment:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER